Investigational drug · Phase 2
AZD4512
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for B-cell Non-Hodgkin Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AZD4512"
First trial start
2025
Sep 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD4512", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-cell Non-Hodgkin Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD4512" as an intervention, largest first.
AstraZenecaAstraZeneca (AZN)
NCT07123454 · 164 participants (planned) · Start Sep 24, 2025 · Primary completion Jul 4, 2028
Drug: AZD4512; Surovatamig · For: B-cell Non-Hodgkin Lymphoma
Sites: Irvine, California; Jacksonville, Florida; Rochester, Minnesota · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for B-cell Non-Hodgkin Lymphoma
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- DS3790aPhase 21 trial
Daiichi Sankyo · Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
- HP-002Phase 21 trial
Shanghai Helioson Pharmaceutical Co., Ltd. · B-Cell Non-Hodgkin Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.